Literature DB >> 1598899

Evidence for genetic heterogeneity of malignant hyperthermia susceptibility.

T Deufel1, A Golla, D Iles, A Meindl, T Meitinger, D Schindelhauer, A DeVries, D Pongratz, D H MacLennan, K J Johnson.   

Abstract

A locus for malignant hyperthermia susceptibility (MHS) has been localized on chromosome 19q12-13.2, while at the same time the gene encoding the skeletal muscle ryanodine receptor (RYR1) also has been mapped to this region and has been found to be tightly linked to MHS. RYR1 was consequently postulated as the candidate for the molecular defect causing MHS, and a point mutation in the gene has now been identified and is thought to be the cause of MH in at least some MHS patients. Here we report the results of a linkage study done with 19q12-13.2 markers, including the RYR1 cDNA, in two Bavarian families with MHS. In one of the families, three unambiguous recombination events between MHS and the RYR1 locus were found. In the second family only one informative meiosis was seen with RYR1. However, segregation analysis with markers for D19S75, D19S28, D19S47, CYP2A, BCL3, and APOC2 shows that the crossovers in the first family involve the entire haplotype defined by these markers flanking RYR1 and, furthermore, reveals multiple crossovers between these haplotypes and MHS in the second family. In these families, pairwise and multipoint lod scores below -2 exclude MHS from an interval spanning more than 26 cM and comprising the RYR1 and the previously described MHS locus. Our findings thus strongly suggest genetic heterogeneity of the MHS trait and prompt the search for another MHS locus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1598899      PMCID: PMC1682579     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

1.  Assignment of the gene for central core disease to chromosome 19.

Authors:  E A Haan; C J Freemantle; J A McCure; K L Friend; J C Mulley
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

2.  Evidence for linkage of the central core disease locus to the proximal long arm of human chromosome 19.

Authors:  K Kausch; F Lehmann-Horn; M Janka; B Wieringa; T Grimm; C R Müller
Journal:  Genomics       Date:  1991-07       Impact factor: 5.736

3.  Definition of subchromosomal intervals around the myotonic dystrophy gene region at 19q.

Authors:  D Schonk; M Coerwinkel-Driessen; I van Dalen; F Oerlemans; B Smeets; J Schepens; T Hulsebos; D Cockburn; Y Boyd; M Davis
Journal:  Genomics       Date:  1989-04       Impact factor: 5.736

Review 4.  Malignant hyperthermia: a statistical review.

Authors:  B A Britt; W Kalow
Journal:  Can Anaesth Soc J       Date:  1970-07

5.  A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia.

Authors:  A E MacKenzie; G Allen; D Lahey; M L Crossan; K Nolan; G Mettler; R G Worton; D H MacLennan; R Korneluk
Journal:  Anesthesiology       Date:  1991-07       Impact factor: 7.892

6.  Recombination events that locate myotonic dystrophy distal to APOC2 on 19q.

Authors:  K Johnson; P Shelbourne; J Davies; J Buxton; E Nimmo; M Anvret; M Bonduelle; B Williamson; M L Savontaus
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

7.  A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia.

Authors:  E F Gillard; K Otsu; J Fujii; V K Khanna; S de Leon; J Derdemezi; B A Britt; C L Duff; R G Worton; D H MacLennan
Journal:  Genomics       Date:  1991-11       Impact factor: 5.736

8.  Evidence for genetic heterogeneity in malignant hyperthermia susceptibility.

Authors:  R C Levitt; N Nouri; A E Jedlicka; V A McKusick; A R Marks; J G Shutack; J E Fletcher; H Rosenberg; D A Meyers
Journal:  Genomics       Date:  1991-11       Impact factor: 5.736

9.  Cosegregation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine receptor gene in backcross families.

Authors:  K Otsu; V K Khanna; A L Archibald; D H MacLennan
Journal:  Genomics       Date:  1991-11       Impact factor: 5.736

10.  Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia.

Authors:  J Fujii; K Otsu; F Zorzato; S de Leon; V K Khanna; J E Weiler; P J O'Brien; D H MacLennan
Journal:  Science       Date:  1991-07-26       Impact factor: 47.728

View more
  13 in total

1.  Genetic heterogeneity in Schwartz-Jampel syndrome: two families with neonatal Schwartz-Jampel syndrome do not map to human chromosome 1p34-p36.1.

Authors:  K A Brown; L I al-Gazali; L M Moynihan; N J Lench; A F Markham; R F Mueller
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

2.  Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit.

Authors:  Antonella Pirone; Johann Schredelseker; Petronel Tuluc; Elvira Gravino; Giuliana Fortunato; Bernhard E Flucher; Antonella Carsana; Francesco Salvatore; Manfred Grabner
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

3.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.

Authors:  N Monnier; V Procaccio; P Stieglitz; J Lunardi
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Ryanodine receptor gene point mutation and malignant hyperthermia susceptibility.

Authors:  I Moroni; E F Gonano; G P Comi; V Tegazzin; A Prelle; A Bordoni; N Bresolin; G Scarlato
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

Review 5.  Investigation of muscle disease.

Authors:  F L Mastaglia; N G Laing
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

6.  Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families.

Authors:  R Robinson; J L Curran; W J Hall; P J Halsall; P M Hopkins; A F Markham; A D Stewart; S P West; F R Ellis
Journal:  J Med Genet       Date:  1998-03       Impact factor: 6.318

7.  Refined genetic localization for central core disease.

Authors:  J C Mulley; H M Kozman; H A Phillips; A K Gedeon; J A McCure; D E Iles; R G Gregg; K Hogan; F J Couch; D H MacLennan
Journal:  Am J Hum Genet       Date:  1993-02       Impact factor: 11.025

8.  Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene.

Authors:  T Deufel; R Sudbrak; Y Feist; B Rübsam; I Du Chesne; K L Schäfer; N Roewer; T Grimm; F Lehmann-Horn; E J Hartung
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

9.  Voltage-dependent calcium release in human malignant hyperthermia muscle fibers.

Authors:  A Struk; F Lehmann-Horn; W Melzer
Journal:  Biophys J       Date:  1998-11       Impact factor: 4.033

Review 10.  The genetics of malignant hyperthermia.

Authors:  S P Ball; K J Johnson
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.